Fight CRC Clinical Trial Finder
| NCT ID | Title | 阶段 | Date Added | 地点 | Prior IO Allowed | CRC-directed | Status | 药物 | 标签 |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT05999812 |
TitleClinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Colorectal Cancer | 阶段
第二阶段
|
Date Added 2023-08-21 |
地点
Texas, United States
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
all trans Retinoic Acid, Atezolizumab, Bevacizumab |
标签
MSS/ MMRp
|
| NCT ID NCT06006923 |
TitleRegorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer | 阶段
第二阶段
|
Date Added 2023-08-23 |
地点
California, United States
Florida, United States Illinois, United States Pennsylvania, United States Washington, United States |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
Pembrolizumab, Regorafenib, Keytruda, Stivarga |
标签
MSI-H/ MMRd
|
| NCT ID NCT06014502 |
TitleStudy to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors | 阶段
第 1 阶段
|
Date Added 2023-08-28 |
地点
Louisiana, United States
Texas, United States |
Prior IO Allowed 没有 |
CRC-directed 没有 |
Status
招聘
|
药物
IMGS-001 |
标签
MSI-H/ MMRd
|
| NCT ID NCT06176885 |
TitleEfficacy and Safety of Combined With Immunotherapy After Induction Therapy With Chemotherapy and Targeted Therapy in the First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer | 阶段
第二阶段
|
Date Added 2023-12-20 |
地点
中国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
Camrelizumab |
标签
MSS/ MMRp
|
| NCT ID NCT06106308 |
TitleStudy of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation | 阶段
第二阶段
|
Date Added 2023-10-30 |
地点
Arizona, United States
Arkansas, United States California, United States Florida, United States Hawaii, United States Indiana, United States Kansas, United States Michigan, United States Minnesota, United States Missouri, United States Nevada, United States New York, United States Ohio, United States Oregon, United States Pennsylvania, United States Tennessee, United States Texas, United States Utah, United States Virginia, United States Washington, United States Wisconsin, United States |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Bevacizumab, FOLFIRI, FOLFOX, Onvansertib |
标签
MSS/ MMRp
|
| NCT ID NCT06107413 |
TitleStudy to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab | 阶段
第二阶段
|
Date Added 2023-10-30 |
地点
Arizona, United States
Arkansas, United States California, United States Connecticut, United States Florida, United States Illinois, United States Indiana, United States Louisiana, United States Minnesota, United States North Carolina, United States South Carolina, United States South Dakota, United States Texas, United States Virginia, United States 比利时 德国 以色列 日本 大韩民国 西班牙 台湾 |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
ABBV-400, Bevacizumab, fluorouracil, Folinic acid, Irinotecan |
标签
MSS/ MMRp
|
| NCT ID NCT05286814 |
TitleM9241 与肝动脉输注泵 (HAIP) 和全身疗法联合用于转移性结直肠癌或肝内胆管癌患者的治疗 | 阶段
第二阶段
|
Date Added 2022-03-18 |
地点
Maryland, United States
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物 |
标签
MSS/ MMRp
|
| NCT ID NCT04041310 |
TitleNous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors | 阶段
Phase 1, Phase 2
|
Date Added 2019-08-01 |
地点
California, United States
Florida, United States Indiana, United States Maryland, United States Missouri, United States New York, United States Texas, United States 比利时 加拿大 意大利 西班牙 英国 |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物 |
标签
MSI-H/ MMRd
|
| NCT ID NCT05865535 |
TitleA Dose Escalation Study of AV-380 in Metastatic Cancer Patients With Cachexia | 阶段
第 1 阶段
|
Date Added 2023-05-19 |
地点
California, United States
Florida, United States Georgia, United States Nebraska, United States New York, United States Oregon, United States South Carolina, United States Tennessee, United States Texas, United States |
Prior IO Allowed 没有 |
CRC-directed 没有 |
Status
招聘
|
药物 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
